Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Stryker Corporation — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.95, while Stryker Corporation trades at $346.82 (market cap $133.54B). The key difference: Stryker Corporation pays a 1.01% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| JEPQ | SYK | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $61.46 | $394.34 |
52-Week Low | $53.77 | $282.58 |
Market Cap | — | $133.54B |
Enterprise Value | — | $145.01B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.00, up 0.54% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates monthly income, with recent dividends of $0.70, $0.64, and $0.56. News highlights focus on retirement income strategies and tax implications of distributions. Institutional interest remains strong, with Bank of America increasing its stake by 8.9% in Q1 2026.
Outlook remains positive for income-focused investors, though the RSI suggests potential overbought conditions. Key risks include tax treatment of distributions and market volatility affecting the options strategy. The fund's $39 billion AUM and active management support its popularity for yield generation in retirement portfolios.
Stryker (SYK) trades at $347.21, up 0.4% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals, including a 9% organic sales growth in Q2 2026 and a net income margin of 14.43%. Recent news highlights recovery from a cybersecurity incident and the launch of Mako RPS, expanding its robotic surgery portfolio. Analyst consensus is overwhelmingly positive, with 74% recommending Buy and a price target of $379.44.
The outlook for SYK is favorable, driven by robust earnings growth and strategic product launches. Key risks include cybersecurity vulnerabilities and margin pressures from tariffs. With no sell ratings and strong institutional support, the stock presents a compelling opportunity for growth-oriented investors, though monitoring quarterly execution remains critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
